A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants

Phase 3

Not yet recruiting

• Conditions: Poliomyelitis
• Interventions: Biological: nOPV2

• Registration Number: NCT07010822
• Lead Sponsor: Fidec Corporation

Brief Summary

The study will compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).

Detailed Description

To meet the urgent public health need regarding cVDPV2 outbreaks, a novel type 2 OPV (nOPV2) vaccine was developed using attenuated serotype 2 polioviruses derived from a modified Sabin 2 infectious cDNA clone generated by modifying the Sabin-2 ribonucleic acid (RNA) sequence to improve genetic stability and make the strains less prone to reversion to virulence. Clinical trials in adults, children, and infants demonstrated that nOPV2 vaccine is safe, well tolerated, and immunogenic. These include a phase 2 study of vaccine-naïve neonates in Bangladesh who received either two doses of nOPV2 or two doses of placebo at birth and 4 weeks of age concluded that the vaccine was well tolerated and immunogenic, as 90% of the infants seroconverted at 2 weeks post second dose. Overall 99% of infants had protective levels of neutralizing antibody at this time in contrast to the seroprotection rate of 56% in the placebo group.

Although immunogenic, the effect of nOPV2 on virus transmission is still unclear. This phase 3 study aims to compare the transmissible levels of poliovirus type-2 detected in stool samples collected at the time of the nOPV2 challenge (pre-challenge) and subsequent timepoints in 3 groups of newborns receiving an nOPV2 dose at birth and primed with 3 doses of IPV (6 - 10 - 14 weeks of age).

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-30
• Study First Submitted QC: 2025-06-06
• Last Update Submitted: 2025-06-06
• Study First Posted: 2025-06-08
• Last Update Posted: 2025-06-08
• Study Start: 2025-12-08
• Primary Completion: 2026-09-21
• Study Completion: 2026-09-21

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 740

Inclusion Criteria

1. Newborn infants of maximum 1 week of age with birth weight > 2,500 g.
2. Healthy infants without obvious medical conditions like immunodeficiency diseases, severe congenital malformations, severe neurological diseases or any other disease that require high doses of corticosteroids or immunotherapies that preclude the subject from participating in the study as established by medical history and physical examination.
3. Written informed consent obtained from both parents or legal guardian(s) as per country regulations.

Exclusion Criteria

1. Any confirmed or suspected immunosuppressive or known immunodeficient condition including human immunodeficiency virus infection in the potential participant or any member of the subject's household.
2. Family history of congenital or hereditary immunodeficiency.
3. Major congenital defects or serious uncontrolled chronic illness (neurologic, pulmonary, gastrointestinal, hepatic, renal, or endocrine).
4. Known allergy to any component of the study vaccines or to any antibiotics that share molecular composition with a component of the study vaccines.
5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular injections (of IPV)
6. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
7. Acute severe febrile illness on the day of vaccination deemed by the Investigator to be a contraindication for vaccination (the child can be included at a later time if within age window and all inclusion criteria are met.).
8. Subject who, in the opinion of the Investigator, is unlikely to comply with the protocol or is inappropriate to be included in the study for the safety or the benefit-risk ratio of the subject.
9. Infants from multiple births or born prematurely (< 37 weeks of gestation).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
nOPV2 at birth	nOPV2	Approximately 330 subjects to receive 1 dose of nOPV2 at birth followed by a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
nOPV2 at birth and Wk 14 of age	nOPV2	Approximately 80 subjects to receive 2 doses of nOPV2 at birth and 14 wks of age plus a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age.
Placebo	nOPV2	Approximately 330 subjects to receive 2 doses of placebo at birth and 14 wks of age plus a regular IPV schedule at approx. 6, 10, 14 weeks of age and an nOPV2-002 challenge at approx. 18 weeks of age

Primary Outcome Measures

Name	Time	Method
Stool viral load	From enrollment to the end of the study at Wk 22 of age.	To assess and compare the transmissible levels of virus, defined as a log10 CCID50 per gram of \>=4.0 at Visit 7 (Day 1 26; day of nOPV2 challenge dose administration) , Visit 8 (Day 130), Visit 9 (Day 133), Visit 10 (Day 140), and Visit 11 (Day 154) in all groups.

Secondary Outcome Measures

Name	Time	Method
PV Type 2 neutralizing activity in stool samples	From enrollment to the end of the study at 22 Wks of age.	To assess poliovirus type-2-specific neutralizing activity and total concentrations and poliovirus type-2-specific IgA/IgG mean fluorescence intensities (MFI) in stool samples at Visit 7 (Day 126), Visit 8 (Day 130), Visit 9 (Day 133), Visit 10 (Day 140), and Visit 11 (Day 154).
PV Type 2 AUC and SIE in stool samples	From enrollment to the end of the study at 22 Wks of age	To assess the area under the curve (AUC) of shed poliovirus type-2 and Shedding Index Endpoint (SIE) of poliovirus type-2 expressed as the mean poliovirus type 2 viral titer (log10 CCID50 per gram) from stool samples collected at Visit 7 (Day 126; day of nOPV2 challenge dose administration), Visit 8 (Day 130), Visit 9 (Day 133), Visit 10 (Day 140), and Visit 11 (Day 154).
PV Type 2 seroprotection rate	From enrollment till 18 Wks of age	To assess the seroprotection (SP) rate to poliovirus type-2 on Week 6 (Visit 4) of age. Seroprotection rate is defined as the percentage of subjects with type 2-specific antibody titers ≥ 1:8.
PV Type 2 seroconversion rate	From enrollment till Wk 18 of age.	To assess the seroconversion (SC) rate of poliovirus type-2 neutralizing on Week 18 (Visit 7) of age.
PV Type 2 neutralization titers	From enrollment till Wk 18 of age	To assess the geometric mean and median poliovirus type-2-specific neutralization titers on Week 6 (Visit 4) and Week 18 (Visit 7) of age.
SAEs and IMEs	From enrollment to the end of the study at Wk 22 of age	Incidence of SAEs and IMEs by severity and by causal association from the date of informed consent throughout the study period in all groups.
Solicited AEs	From enrollment to Wk 18 of age	Incidence of mild, moderate and severe solicited AEs (fever, vomiting, abnormal crying, drowsiness, loss of appetite, diarrhea and irritability) for 7 days after each dose of study vaccine/placebo in all groups.

Trial Locations

Locations (1)

icddr,b - Matlab Health Research Centre; 🇧🇩 Chandpur, Dhaka, Bangladesh

icddr,b - Matlab Health Research Centre

🇧🇩Chandpur, Dhaka, Bangladesh

Khaelqu Zaman, Dr.

Principal Investigator

Warda Haque

Contact

+880 1720-289260

warda.haque@icddrb.org